Carlyle Group/Abingworth Reduces Stake Below 5% in Jasper Therapeutics
Summary
The Carlyle Group and its affiliates, including Abingworth Bioventures VII LP, have reported that their beneficial ownership in Jasper Therapeutics, Inc. has fallen below the 5% threshold.
Key Events
-
Ownership Reduction Below 5%
The Carlyle Group and its affiliates now beneficially own 1,088,310 shares, representing 3.8% of Jasper Therapeutics' common stock, down from a previous stake above 5%.
-
Passive Reduction
The filing explicitly states that the reporting persons have not effected any transactions in the past 60 days, indicating that the reduction below the 5% threshold was likely due to an increase in the total outstanding shares of Jasper Therapeutics (dilution).
Analysis
This Schedule 13D/A filing reports that The Carlyle Group and its affiliated entities, including Abingworth Bioventures VII LP, are no longer a significant 5%+ shareholder in Jasper Therapeutics. While the filing explicitly states no transactions were effected by the reporting persons in the past 60 days, suggesting the reduction below 5% was primarily due to dilution from the company's share issuance, the change in ownership status is still notable. The reduction of a major institutional investor's stake below a key reporting threshold can be perceived negatively by the market, as it reduces institutional oversight and potential support. Investors should monitor future capital raises or share issuances by Jasper Therapeutics and any further changes in institutional holdings.
At the time of this filing, JSPR was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $1.11 to $7.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.